• 12076 Citations
  • 37 h-Index
1977 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 9 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Lung Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Survival Medicine & Life Sciences
Clinical Trials, Phase I Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1977 2019

Open Access
Internet
Observational Studies
Decision Making
Cross-Sectional Studies
Physicians

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies

Bhatty, M., Kato, S., Piha-Paul, S. A., Naing, A., Subbiah, V., Huang, H. J., Karp, D. D., Tsimberidou, A. M., Zinner, R. G., Hwu, W-J., Javle, M., Patel, S. P., Hu, M. I-N., Varadhachary, G. R., Conley, A. P., Ramzanali, N. M., Holley, V. R., Kurzrock, R., Meric-Bernstam, F., Kwang Chae, Y. & 3 othersKim, K. B., Falchook, G. S. & Janku, F., Feb 1 2019, In : Cancer. 125, 3, p. 463-472 10 p.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Melanoma
Mitogen-Activated Protein Kinase Kinases
Neoplasms
1 Citation (Scopus)
Triple Negative Breast Neoplasms
Breast Neoplasms
Therapeutics
Disease-Free Survival
Phosphatidylinositol 3-Kinases
2 Citations (Scopus)
Clinical Trials, Phase I
Confidence Intervals
Neoplasms
Survival
Clinical Trials